SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

Gluco6 is a natural blood sugar support supplement emerging as a popular choice in the ever-growing market of anti-diabetic ...

In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk ...

When it comes to bitter tastes, lemons, coffee, or even Brussels sprouts might spring to mind. But these foods pale in ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Blockbuster weight loss drugs like Ozempic could leave users at a higher risk of depression and suicidal thoughts, a ...

Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with T2D.

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

While sprinkling cinnamon on food is likely safe, concentrated supplements might pose risks, especially for people taking ...